Abstract
Patients with chronic colitis from inflammatory bowel disease (IBD), whether ulcerative colitis or Crohn’s disease, have an increased risk of colorectal cancer (CRC), which accounts for approximately 10–15% of all deaths among IBD patients. The risk of CRC increases with disease duration and is frequently preceded by the pre-cancerous histological stage called dysplasia. In an attempt to detect dysplasia and asymptomatic cancers in patients with IBD, most national gastroenterology societies recommend initiating colonoscopy surveillance after 8 to 10 years of diagnosis. The goal of surveillance is to reduce the risk of cancer and mortality due to CRC. Current studies of surveillance using chromoendoscopy (dye spray) have demonstrated improved detection of dysplasia compared to conventional colonoscopy surveillance and have changed the approach from random to targeted biopsies. In this article, Saqib Ahmad and Krish Ragunath aim to discuss chromoendoscopy in detail with brief discussion about management of dysplasia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
